Clinical Trials Logo

Cholinergic Urticaria clinical trials

View clinical trials related to Cholinergic Urticaria.

Filter by:
  • None
  • Page 1

NCT ID: NCT06201780 Recruiting - Clinical trials for Cholinergic Urticaria

Assessment of Serum Levels of Janus Kinase 1 and 2 in Patients With Cholinergic Urticaria

Start date: December 15, 2023
Phase: N/A
Study type: Interventional

Cholinergic Urticaria (CholU) is as a subtype of CIndU caused by an increase in the core body temperature, such as to activate the sweating reflex. It can occur in response to physical exercise, hot bathing and/or emotional stress. Clinically it appears as pinpointing and highly pruritic wheals with surrounding erythema, CholU can be accompanied by severe symptoms such as angioedema, respiratory symptoms or anaphylaxi CholU is frequently associated with atopic dermatitis (AD) The JAK-STAT is a mast cell (MC) signaling pathway activated downstream of IgE and IL-3 with important roles in MC homeostasis via regulation of proliferation, survival, and release of mediators. JAK-STAT activation is associated with polarization toward Th2, B cell isotype switching to IgE production, and IgE-dependent degranulation and cytokine release . Because both IL-4 and IL-13 use the IL-4Rα as a receptor component, these cytokines activate any common signaling pathways. Both of these cytokines use Janus kinases (JAKs) to initiate signaling and activate signal transducer and activator of transcription-6 (STAT6), which is a transcription factor required for many of their biologic functions. The non-receptor protein tyrosine kinases JAK1 and JAK3 associate with the IL-4Rα and γC, respectively. The binding of IL-4 to its receptor induces the transphosphorylation of JAK1 and JAK3, an event that activates these kinases and thereby initiates the early events of signal transduction .

NCT ID: NCT04853992 Completed - Clinical trials for Cholinergic Urticaria

Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria

Start date: May 10, 2021
Phase: Phase 2
Study type: Interventional

Phase 2a trial to assess the efficacy and safety of LEO 152020 in adult patients with cholinergic urticaria

NCT ID: NCT04548869 Completed - Clinical trials for Cholinergic Urticaria

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria

Start date: November 24, 2020
Phase: Phase 1
Study type: Interventional

This is a study to determine the safety of CDX-0159 in patients with Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria.

NCT ID: NCT04513548 Terminated - Clinical trials for Chronic Spontaneous Urticaria

Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria

MASTER
Start date: August 5, 2020
Phase: Phase 1
Study type: Interventional

The purpose of the study is to investigate the mechanism of action for ligelizumab (QGE031) treatment in patients with chronic urticaria. The study has two parts. The study population will consist of approximately 68 male and female healthy volunteers and patients. In Part 1, approximately 20 healthy volunteers and patients with chornic urticaria will be enrolled. In Part 2 approximately 48 patients with chronic urticaria (spontaneous chronic urticaria, cholinergic urticaria or cold urticaria). Part 1 consists of a screening period up 2 weeks and a visit with skin tests; there is no treatment taken in Part 1. Part 2 is randomized, subject, investigator and sponsor blinded. It consists of a screening period up to 4 weeks, a 16 week treatment period and a 12-week follow-up period after last treatment. A follow-up call at Week 32 will be performed via telephone.

NCT ID: NCT03749148 Completed - Clinical trials for Cholinergic Urticaria

Cholinergic Urticaria - Efficacy of Dupilumab

CHED
Start date: December 10, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy in reducing disease activity and safety of Dupilumab in adult patients with cholinergic urticarial (CholU) who are symptomatic despite H1-antihistamine treatment (licensed dose).

NCT ID: NCT02012387 Completed - Clinical trials for Cholinergic Urticaria

Efficacy Study of Omalizumab in Cholinergic Urticaria

CUN-OMAL-UCOL
Start date: January 2014
Phase: Phase 2
Study type: Interventional

To demonstrate the efficacy and safety of Omalizumab in a new indication, that is cholinergic urticaria.